堀井 俊宏

Publication

• (1) Molecular Camouflage of Plasmodium falciparum Merozoites by Binding of Host Vitronectin to P47 Fragment of SERA5. Tougan T., et al., Sci Rep. (2018) 8:5052. doi: (5)10.1038/s41598-018-23194-9.
• (2) Antibody titres and boosting after natural malaria infection in BK-SE36 vaccine responders during a follow-up study in Uganda. Yagi M., et al., Sci Rep. (2016) 6:34363. doi: 10.1038/srep34363.
• (3) Protective Epitopes of the Plasmodium falciparum SERA5 Malaria Vaccine Reside in Intrinsically Unstructured N-Terminal Repetitive Sequences.Yagi M., et al., PLoS One. (2014) 9:e98460. doi: 10.1371/journal.pone.0098460.
• (4) Phase 1b randomized trial and follow-up study in Uganda of the blood-stage malaria vaccine candidate BK-SE36. Palacpac N.M.Q., et al., PLoS ONE. (2013) 8: e64073. doi:10.1371/journal.pone.0064073
• (5) Plasmodium falciparum serine repeat antigen 5 (SE36) as a malaria vaccine candidate. Palacpac N.M., et al., Vaccine. (2011) 29:5837-45. doi: 10.1016/j.vaccine.2011.06.052.
• (6) Evidences of Protection Against Blood-stage Infection of Plasmodium falciparum by the Novel Protein Vaccine SE36. Horii T., et al., Parasitol. Int. (2010) 59:380-6. doi: 10.1016/j.parint.2010.05.002.